60 Degrees Pharma grants U of Kentucky a right of reference to ARAKODA® NDA for a Phase IIb trial combining SJ733 with tafenoquine to treat vivax malaria.
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
GSK plc and Medicines for Malaria Venture (MMV) announce that the first single-dose medicine for the prevention of relapse of Plasmodium vivax (P. vivax) malaria – tafenoquine, co-administered with chloroquine for radical cure, has now been launched in both Thailand and Brazil, in support of malaria elimination efforts.
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.
60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.
SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.